Osteoarthritis affects an estimated 20% of dogs over one year of age, rising sharply in larger breeds and seniors. While pharmaceutical interventions remain the primary clinical tool, nutritional strategies — particularly long-chain omega-3 fatty acids — have attracted significant research interest over the past decade.

EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), derived primarily from marine sources, are precursors to anti-inflammatory eicosanoids. In a landmark 2010 study published in the Journal of the American Veterinary Medical Association, dogs with osteoarthritis fed a diet enriched with fish oil showed statistically significant improvements in weight-bearing and veterinarian-assessed pain scores compared to controls.

Subsequent work has refined our understanding of dosing. A 2016 meta-analysis in the Journal of Veterinary Internal Medicine concluded that a minimum daily intake of 75–100 mg EPA+DHA per kilogram of body weight (metabolic weight) was required to produce clinically meaningful anti-inflammatory effects. Below this threshold, benefits were inconsistent.

Bioavailability matters as much as dose. Triglyceride-form omega-3s — as opposed to ethyl ester forms common in lower-cost supplements — demonstrate approximately 70% greater absorption in canine gastrointestinal studies. K9 Health's Mobility+ uses triglyceride-form marine oil to ensure the dose on the label translates to the dose in the bloodstream.

Practical considerations include oxidative stability. Omega-3 oils are highly susceptible to rancidity, which not only degrades potency but may introduce harmful oxidation products. Cold-chain handling and nitrogen-flushed packaging are not optional extras — they are prerequisites for a supplement that actually delivers what it promises.

The canine gut microbiome — the community of trillions of bacteria, fungi, and other microorganisms inhabiting the gastrointestinal tract — has emerged as one of the most consequential factors in long-term canine health. Far from being a passive digestive aid, the microbiome actively modulates immune responses, produces neuroactive compounds, and influences metabolic pathways that govern ageing itself.

A 2019 study in the journal Microbiome characterised the gut microbiota of 64 dogs across different age groups and health statuses. Older dogs with lower microbiome diversity showed elevated circulating levels of lipopolysaccharide-binding protein — a marker of systemic endotoxaemia — alongside higher inflammatory cytokine profiles. The authors concluded that microbiome dysbiosis may be a driver, not merely a consequence, of age-related inflammation.

Specific bacterial genera have been associated with favourable outcomes. Higher relative abundance of Faecalibacterium, a major producer of the short-chain fatty acid butyrate, correlates with lower intestinal permeability and reduced systemic inflammation in both human and canine studies. Conversely, enrichment of Clostridiales and Fusobacterium has been associated with inflammatory bowel disease and certain cancers in dogs.

Dietary fibre is the primary substrate for beneficial microbiota. Fermentable fibres — including inulin, fructooligosaccharides (FOS), and certain resistant starches — selectively feed Bifidobacterium and Lactobacillus species while suppressing pathogenic bacteria. A 2021 randomised controlled trial in dogs demonstrated that supplementation with a blend of inulin and FOS for 28 days significantly increased Faecalibacterium abundance and reduced faecal pH, both markers of a healthier microbial environment.

The gut-brain axis adds another dimension. Approximately 90% of the body's serotonin is produced in the gut, and canine studies have linked microbiome composition to anxiety-related behaviours and cognitive function in ageing dogs. Supporting gut health is not merely a digestive intervention — it is a whole-body longevity strategy.